Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers

Inclusion Criteria:

1. Male or female, ≥18 years of age
2. For the Pharmacokinetic Drug Interaction Study: Histologically or cytologically confirmed advanced solid tumors that are refractory to all standard of care therapy or for whom no standard therapy is available, or for whom other standard therapies the patient has denied. For the Pharmacodynamic Study: Histologically or cytologically confirmed metastatic/advanced ovarian carcinoma or metastatic/advanced KRAS mutant colorectal cancer or metastatic/advanced HNSCC that are refractory to all standard therapies therapy or for whom no standard therapy is available, or for whom other standard therapies the patient has denied.
3. At least one measurable tumor as defined by RECIST
4. Minimum of 4 weeks since any major surgery, completion of radiation, or completion of all prior systemic anticancer therapy
5. ECOG of 0 to 2
6. Organ &marrow function as defined in the protocol.
7. No evidence of preexisting uncontrolled hypertension as documented by two baseline blood pressure readings taken at least 1 hour apart
8. Clinically euthyroid
9. Normal range cardiac function
10. For female patients of child-bearing potential, a negative serum pregnancy test at Screening.
11. Current use of an acceptable form of double-barrier birth control
12. Have provided written informed consent

Exclusion Criteria:

1. Known brain or other central nervous system metastases metastases that are not stable for 3 months or longer
2. Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation.
3. Major surgery, radiotherapy, chemotherapy, or cytokine therapy within 28 days of Study Day 0;
4. History of intratumoral bleeding or evidence of bleeding diathesis or coagulopathy
5. Female patients who are pregnant, planning a pregnancy, or who are breastfeeding
6. Known allergy or hypersensitivity to JI-101 or everolimus or any component of the investigational products
7. Use of an investigational drug/device/biologic within 28 days of Study Day 0
8. Current drug or alcohol abuse or history of drug or alcohol abuse within the past two years
9. Known history of or serologic positivity for the Hepatitis B Virus (HBV), or the Hepatitis C Virus (HCV), or for the human immunodeficiency virus (HIV)
10. History of cardiac abnormalities
11. Gastrointestinal (GI) abnormalities
12. Use of concomitant medications that prolong the QT/QTc interval within 14 days prior to Study Day 0
13. History of cerebrovascular accident including transient ischemic attack within the past 6 months
14. History of pulmonary embolism or deep vein thrombosis within the past 6 months
15. History of significant retinopathy or any progressive eye disease that could lead to severe loss of visual acuity or visual field loss during the study period
16. Treatment with heparin or heparin analogs
17. Inability or unwillingness to meet the requirements of the study
18. Other current active malignancy or history of malignancy within the past five years, except for cervical carcinoma in situ, basal cell carcinoma that has been surgically removed, or prostate cancer that is being managed with watchful waiting.
19. Any clinically significant abnormal finding at screening that the investigator judges would interfere with study participation